Controversial Alzheimer’s Drug Faces Critical Test Before F.D.A. Panel your-feed-science, Alzheimer's Disease, Drugs (Pharmaceuticals), Clinical Trials
By BY PAM BELLUCK from NYT Health https://nyti.ms/2I5qxvA
If ultimately approved, the drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. Some evidence suggests it slows, but does not stop, cognitive decline.